Skip to content

Author

A. Awashra

We have 5 of 149 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

FGF23 –Klotho Axis Dysregulation in Type 4 Cardiorenal Syndrome: Molecular Mechanisms, Paediatric Perspectives, and Emerging Therapeutic Targets

Cardiorenal syndrome (CRS) represents a bidirectional interplay between cardiac and renal dysfunction, but CRS cases involving paediatric patients represent only a minority of cases overall. CRS type‐4 (CRS4), a long‐term reno‐cardiac syndrome driven by chronic kidney disease (CKD), is not the most frequently reporte...

Mohammed AbuBaha, S. Aldwaik, Ahmad Nouri et al. · 0 citations
Open access Aug 2026

Clinical and procedural outcomes of IVUS-guided versus angiography-guided PCI in unprotected left main coronary disease: An updated meta-analysis of randomized controlled trials.

BACKGROUND The clinical benefit of intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) in patients with unprotected left main coronary artery disease (ULMCAD) remains uncertain. We performed an updated meta-analysis of randomized controlled trials (RCTs) comparing IVUS-guided versus angiogra...

A. Emara, A. Awashra, A. Mansour et al. · 0 citations
Review Aug 2026

Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement: A Meta-analysis.

BACKGROUND Stroke prevention after transcatheter aortic valve replacement (TAVR) in patients with atrial fibrillation remains clinically challenging because thromboembolic risk must be balanced against substantial bleeding vulnerability. Left atrial appendage occlusion (LAAO) has been proposed as a nonpharmacologic alt...

Mustafa Abomohsen, Amr Elboliney, A. Mohamed et al. · 0 citations
Review Aug 2026

Efficacy and Safety of Baxdrostat for Patients With Uncontrolled or Resistant Hypertension: A Systematic Review and Meta-Analysis.

Baxdrostat lowers blood pressure and aldosterone levels in uncontrolled and resistant hypertension but increases potassium and modestly reduces eGFR, supporting careful laboratory monitoring and longer trials to evaluate long-term clinical outcomes.

A. Gadelmawla, A. Hageen, R. Rateb et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.